The X-ray repair cross-com plem enting group 1 (XRCC1) gene is believed to play an im portant role in base excision repair and displays genetic polym orphism s. Data on the role of XRCC1 polym orphism s in cancer susceptibility is inconsistent. In the present study, w e investigated the effect of tw o XRCC1 polym orphism s, Arg194Trp and Arg399G ln, on breast cancer risk in a casecontrol study involving Turkish breast cancer patients and healthy wom en. Both alleles exhibited a sim ilar distribution am ong cases and controls leading to lack of any significant association betw een the XRCC1 polym orphism s and breast cancer risk, either in hom ozygotes and heterozygotes or com bined. The allele frequency of the codon 194 variant w as very low in cases and healthy individuals (5.3 and 3.9% , respectively) com pared to that of the variant 399Gln allele (39.7 and 37.4% ). O ur results do not support evidence for a role of the XRCC1 polym orphism in developing breast cancer.
Introduction
Breast cancer is the most prevalent common malignancy among women and the incidence is still increasing. A substantial fraction of breast cancer cases is explained by well-established risk factors such as the age at the first child's birth, nulliparity and family history (Madigan et al., 1995) . In the majority of cases the cause of the disease is still obscure. Amino acid substitutions in the DNA repair genes as result of genetic polymorphisms may lead to alterations in DNA repair capacity and affect the susceptibility to cancer. Polymorphic alleles have been described for many DNA repair genes including the genes responsible for nucleotide and base excision repair (Shen et al., 1998; Fan et al., 1999) . Recent data suggest that DNA repair capacity may vary between individuals (Berwick, 2000) and is lower in cancer patients than healthy controls . It has been hypothesized that multiple alleles may act in combination in conferring cancer risk Shen et al., 1998) .
The protein encoded by the XRCC1 gene plays an important role in base excision repair and removes base adducts formed by ionizing radiation and alkylating agents (Yu et al., 1999) . The multi-domain protein interacts with DNA ligase III, DNA polymerase β and poly (ADP-ribose) polymerase in the base excision repair pathway (Kubota et al., 1996; Nash et al., 1997; Masson et al., 1998; Vidal et al., 2001) . It contains a BRCT-1 domain bearing homology to BRCA1 through which it interacts with DNA ligase III (Kubota et al., 1996) and poly (ADP-ribose) polymerase (Masson et al., 1998) . Three polymorphisms (Arg194Trp, Arg280His and Arg399Gln) in the XRCC1 gene have been described . The Arg399Gln polymorphism occurs within the BRCT-1 domain while the Arg194Trp leads to an amino acid substitution in the hydrophobic region of the protein. Since amino acid substitutions in the active sites may result in reduced efficiency to repair DNA damage these polymorphisms may confer increased risk to breast cancer. Concordantly, the codon 399 polymorphism has been shown to affect DNA repair capacity (Lunn et al., 1999) , while the significance of the other two polymorphisms is not yet known.
Previous studies investigating the association between genetic polymorphisms and risk of different cancer types have provided inconsistent results (Ratnasinghe et al., 2001; Stern et al., 2001; Nelson et al., 2002) . Data from studies investigating the association of the XRCC1 polymorphisms with breast cancer risk are also inconsistent (Duell et al., 2001; Kim et al., 2002; Moullan et al., 2003; Shu et al., 2003; Smith et al., 2003a; b) . In the present study, we investigated the effect of two polymorphisms in the XRCC1 gene on breast cancer risk in a Turkish breast cancer population.
Association of the XRCC1 gene polym orphism s with cancer risk in Turkish breast cancer patients

M aterials and M ethods
Our study group consisted of breast cancer patients with similar ethnical background (n = 151; mean age 51.5 ± 11.2; age range 29-75) regardless of menopausal status and family history to evaluate the general cancer risk in unselected cases. Control samples were taken from 133 healthy women (mean age 41 ± 11.3; age range 23-70). Genomic DNA was prepared from blood lymphocytes according to the standard protocol.
Genotyping of the XRCC1 polymorphisms was performed by a multiplex PCR. The reaction mixture contained 2.5 µl 10X reaction buffer, 2.5 mM MgCl2, 200 µM dNTPs, 0.6 µM of each primer, 0.5 µg DNA and 2.0 U of Taq polymerase (Promega, Madison) in a total volume of 25 µl. Primers (Integrated DNA Technologies, Coralville, IA) used were; for codon 194: 5'-GCCCCGTCCCAGGTA-3' (forward) and 5'-AGCCCCAAGACCCTTTCACT-3' (reverse) and for codon 399: 5'-TTGTGCTTTCTCTGTGTCCA-3' (forward) and 5'-TCCTCCAGCCTTTTCTGATA-3' (reverse). The initial denaturation of 5 min at 95 o C was followed by 35 cycles of amplification beginning with a denaturation step of 30 s at 95 o C, annealing for 1 min at 62 o C and extension for 45 s at 72 o C. The reaction was completed by a final extension for 5 min at 72 o C. The products (491 bp and 615 bp for codons 194 and 399, respectively) were resolved on a 1.5% agarose gel containing 5 µg/ml ethidium bromide and visualized under UV-light.
Enzyme digestions of the PCR products were performed in a final volume of 20 µl at 37 o C for 16h using 5 U of HpaII (Promega, Madison). The fragments were separated on 1.5% agarose gels containing ethidium bromide and evaluated using a video gel documentation system (Vilber-Lourmat, Cedex, France).
The enzyme HpaII recognizes the wild-type alleles of codons 194 and 399. It has two recognition sites on the 491 bp fragment at the positions 174 and 198 of which the position 198 is the polymorphic site. Thus, the wild-type allele of codon 194 generates three fragments of 292, 174 and 24 bp, while the variant allele leads to two fragments of 318 and 174 bp. The 174 bp fragment from the digestion of the 491 bp fragment is always present irrespective of the genotype and was used as an internal control for complete digestion.
The enzyme has a single recognition site on the 615 bp fragment. The wild-type allele results in two fragments of 374 and 241 bp; the variant allele is present as an undigested 615 bp fragment.
Statistical analyses were performed using the statistical package Instat + for Windows (Statistical Services Centre; University of Reading, Reading, UK). Odds ratios (ORs) and 95% confidence intervals were calculated.
R esults and D iscussion
Genetic polymorphisms in the DNA repair genes may impair their function and enhance cancer susceptibility. The effect of XRCC1 gene polymorphisms on cancer susceptibility is still not clear and the results up to now are inconsistent (Ratnasinghe et al., 2001; Stern et al., 2001; Nelson et al., 2002) . Studies investigating the association between polymorphisms and breast cancer risk have also led to contradictory results. An association between the 399Gln allele and breast cancer risk among African-American (Duell et al., 2001) and Asian women (Kim et al., 2002) has been suggested by two studies. On the other hand, in a more recent report (Smith et al., 2003a) a weak association for the 194Trp allele, but not for the 399Gln allele was observed in Caucasian women. There are also studies in the literature reporting lack of association between the breast cancer risk and 194Trp and/or the 399Gln polymorphisms in Chinese and French breast cancer patients (Moullan et al., 2003; Shu et al., 2003) . These results suggest that the risk conferred by XRCC1 may vary between ethnic groups.
In this study we investigated the association between the two XRCC1 polymorphisms and breast cancer risk in a homogenous breast cancer population. The frequency of the genotypes was evaluated in breast cancer patients and healthy controls. Figure 1 shows a representative gel for the Arg194Trp and Arg399Gln polymorphisms. The allele frequencies in the healthy controls were consistent with those predicted from the Hardy-Weinberg equilibrium (Table I) .
The variant 399Gln allele is much more common than the variant 194Trp allele in both groups. On the other hand, the allele frequency of the codon 194 
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374 bp 318 bp 292 bp 241 bp 174 bp ------variant was very low in both groups. None of the controls and only one patient harbored the homozygoyte codon 194 variant. Distribution of both variant alleles was similar among the cases and the controls. The frequency of the variant 194Trp allele among the cases is slightly lower than that in healthy controls while the variant 399Gln allele frequency is slightly higher. Similar distribution of the variant alleles led to lack of any significant association between the XRCC1 polymorphisms and breast cancer risk, either in homozygotes and heterozygotes or combined.
The very low frequency of codon 194Trp/Trp genotype in our patients is in accordance with data reported in Caucasian (0-2%) and African-American (0%) (Duell et al., 2001; Stern et al., 2001; Smith et al., 2003b) patients. The frequency of the codon 399Gln/Gln genotype (12%) is also consistent with the reports on Caucasians (13-16%) (Duell et al., 2001; Stern et al., 2001; Nelson et al., 2002; Smith et al., 2003b) . On the other hand, the codon 194Trp/Trp frequency in the Turkish population is considerably lower than that in Asians (13%) (Kim et al., 2002) while the codon 399Gln/Gln frequency is much higher than that of both Asians and African-Americans (Duell et al., 2001; Stern et al., 2001; Kim et al., 2002) .
Our results do not provide evidence for an association between the XRCC1 gene polymorphisms and breast cancer risk in the Turkish population. These data are in concordance with the subgroups in the previous studies. Lack of association between the 399Gln allele and breast cancer is in accordance with data on white American women, Chinese and French breast cancer patients (Duell et al., 2001; Moullan et al., 2003; Shu et al., 2003; Smith et al., 2003a) and lung cancer patients from China (Ratnasinghe et al., 2001) . Lack of association between the 194Trp allele and breast cancer is also consistent with previous reports (Duell et al., 2001; Moullan et al., 2003) . In conclusion, our study suggests that the XRCC1 gene does not provide a susceptibility marker for breast cancer. 
